research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
Search
for
Sort by
Research
780-810 / 1000+ results 
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Topical minoxidil hair loss therapy may cause chest pains and palpitations,
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Anabolic effects of testosterone are preserved during inhibition of 5α-reductase
Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
research Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled
Normal skin cell renewal doesn't need RAR signaling, but vitamin A-related skin thickening does.
research Flutamide
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
research 5‐Alpha reductase inhibitor related litigation: A legal database review
Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
research Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss.
Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.
research The effect of topical RU58841 (androgen receptor blocker) combined with minoxidil on hair growth in macaque androgenetic alopecia
Combining RU58841 and minoxidil significantly increases hair growth.
research Psoriasiform drug eruption to finasteride: Uncommon side effect of a commonly used drug
Finasteride can cause rare but serious skin rashes.
research Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways
Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research FEMALE BREAST CANCER PROTECTION USING PHYTOESTROGEN LIGNANS FROM FLAXSEED
Flaxseed lignans may reduce breast cancer risk in women.
research Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, In Vitro, and In Silico Studies
New compounds show promise as nonsteroidal treatments for hair loss.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Finasteride/hypericum interaction
research Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition
Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research 5α-Reductase Inhibitors (5ARIs) and Male Reproduction
5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases
OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Chronic Exposure of 5‐Alpha Reductase Inhibitor in Young Male Rats Induces Not Only Metabolic Disturbance, But Also Depressive‐Like Behaviors as Similar with Obese Condition
Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
research Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
Some dibenzo compounds might help treat cancer with fewer side effects.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.